JPMorgan Lifts PT on Facebook (FB) to $35; More Positive in 2013 on Mobile Monetization
Tweet
Share
E-mail
Get Alerts FB Hot Sheet
Price: $196.64 --0%
Rating Summary:
46 Buy, 17 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
46 Buy, 17 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
JPMorgan raised its price target on Overweight-rated Facebook (NASDAQ: FB) from $29 to $35.
"We are incrementally positive on Facebook shares into 2013 as we believe it remains very early in the trajectory of Facebook's mobile advertising, and recent marketer feedback on mobile and News Feed ads has been positive," analyst Doug Anmuth states. "We are also encouraged that Facebook's ability to leverage third-party data through the Facebook Exchange (FBX) and Custom Audiences can drive improvements in Desktop yield. We believe Facebookâs advertising revenue will accelerate at least through 1Q13 and we are raising our Advertising estimates 6-7% for 2013 and 2014."
For an analyst ratings summary and ratings history on Facebook click here. For more ratings news on Facebook click here.
Shares of Facebook closed at $26.59 yesterday.
"We are incrementally positive on Facebook shares into 2013 as we believe it remains very early in the trajectory of Facebook's mobile advertising, and recent marketer feedback on mobile and News Feed ads has been positive," analyst Doug Anmuth states. "We are also encouraged that Facebook's ability to leverage third-party data through the Facebook Exchange (FBX) and Custom Audiences can drive improvements in Desktop yield. We believe Facebookâs advertising revenue will accelerate at least through 1Q13 and we are raising our Advertising estimates 6-7% for 2013 and 2014."
For an analyst ratings summary and ratings history on Facebook click here. For more ratings news on Facebook click here.
Shares of Facebook closed at $26.59 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb Co. (BMY) PT Lowered to $64 at Truist Securities
- Teradyne (TER) PT Raised to $125 at TD Cowen
- Sage Therapeutics (SAGE) PT Lowered to $18 at Truist Securities
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
